Navigation Links
Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
Date:3/6/2009

Expanded Dermatology Division of Valeant Pharmaceuticals Introduces Fixed Combination Acne Treatment Designed to Increase Patient Satisfaction and Use

SAN FRANCISCO, March 6 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), announced today the commercial launch of Acanya(TM) Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) indicated for the once-daily treatment of acne vulgaris in patients 12 years and older.

Evaluated in clinical studies enrolling over 3,200 subjects with moderate to severe acne vulgaris, Acanya Gel is the only fixed combination antibiotic and benzoyl peroxide (BPO) medication FDA-approved for the once-daily treatment of both non-inflammatory and inflammatory lesions of acne.

In pivotal Phase III clinical trials, Acanya Gel showed superior efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent tolerability and very high patient satisfaction scores. Results of the 2,813-patient study were reported in the November issue of the Journal of the American Academy of Dermatology.

According to Diane Thiboutot, M.D., a Phase III trial investigator, "Use of combination therapy is recommended at the initiation of acne therapy to inhibit multiple pathogenic factors. The new fixed combination, Acanya Gel, is an effective, safe, and well-tolerated topical product for treating patients with moderate to severe inflammatory and non-inflammatory acne. In addition, high levels of patient satisfaction with Acanya Gel point to the potential for increased patient adherence to treatment, and thus, to improved clinical outcomes."

Phase III Clinical Results

Efficacy: Acanya Ge
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... and Chief Executive Officer, will present at the Morgan Stanley ... , New York on Tuesday, September ... parties are invited to listen to the live audio webcast ... at www.hologic.com/investors-overview . An archive of the presentation will ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ... 9, 2014 at 9:10 a.m. EDT , Aegis ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... September 02, 2014 The new ... to reduce discomfort and fatigue by absorbing stress and ... eco-friendly, renewable bio-foam core, these anti-fatigue mats are intended ... According to a study by the Texas A&M University, ... difference in reducing spinal compression and increase in sit-reach ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... increasing concern to health officials both in NYC and ... Health and Mental Hygiene, the number of unintentional opioid-involved ... of such deaths in 2000. Much of the increase ... prescription opioid (PO) use among teens and young adults, ... transitioned from POs to heroin. , Now researchers ...
(Date:9/2/2014)... new guideline, the Society for Maternal-Fetal Medicine has recommended ... , "There is no evidence that bed rest ... Center for Maternal and Fetal Medicine and one of ... that bed rest can be harmful for moms, babies, ... are placed on bed rest during their pregnancy. Surveys ...
(Date:9/2/2014)... -- Many people believe that marijuana is not addictive, ... more people are able to obtain and consume cannabis ... people are less likely to perceive it as addictive ... Massachusetts General Hospital,s Center for Addiction Medicine, said in ... cannabis use can have significant consequences, and we know ...
Breaking Medicine News(10 mins):Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2Health News:'Pot Addiction' May Be Real, Study Suggests 2
... Alan Mozes HealthDay Reporter , WEDNESDAY, July 20 ... shorter people to develop cancer, new British research says. ... cancer, leukemia or melanoma appears to go up about 16 ... "Taller women in our study had increased risk of ...
... Neurologist Michele Tagliati, MD, director of the Movement ... an elite international task force commissioned by the ... on deep brain stimulation for dystonia, an uncommon ... The resulting articles, describing the data ...
... , WEDNESDAY, July 20 (HealthDay News) -- In a ... Wednesday approved the blood thinner Brilinta (ticagrelor) for use ... their odds for heart attack and death. Acute ... or heart attack linked to lowered blood flow to ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- The race ... New technology promises to cut costs while speeding the amount ... and potentially provide a personalized report of health risks and ... was first mapped in 2001 and cost roughly $1 billion ...
... (HealthDay News) --, Liars can control certain facial expressions when ... time, a new study shows. The researchers noted the ... conducting the study, scientists randomly asked 60 people to either ... pair of movie tickets from an envelope. While being interviewed, ...
Cached Medicine News:Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 2Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 4Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2
... feature a low implant profile, 0.84mm, for ... single-quadrant insertion is technically simpler and allows ... be installed with less trauma than multiple ... Baerveldt implant were designed to minimize bleb ...
... is lightweight enough to shuttle easily between ... Designed with a goldmann standard 30 cm ... with 79 locations (including 30-2, 24-2, and ... different suprathresholds out to 30. Easyfield ...
The most versatile 90 full field perimeter for static- and kinetic perimetry. It incorporates standard White-on-White and Blue-on-Yellow static perimetry. Octopus 101 covers all the needs in clinics ...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Medicine Products: